Christophe Le Tourneau
Senior Medical Oncologist & Professor of Medicine at Institut Curie & Versailles-Saint-Quentin-en-Yvelines University
Christophe Le Tourneau is senior Medical Oncologist at the Institut Curie and Professor of Medicine at the Versailles-Saint-Quentin-en-Yvelines University. He is heading the Department of Drug Development and Innovation as well as the Head and Neck Clinic. Christophe Le Tourneau was certified in Medical Oncology in 2005 and got his PhD in Clinical Epidemiology in 2007.
He did a 2-year Clinical Research Fellowship at Princess Margaret Hospital in Toronto, Canada, in the Drug Development Program. His main interests are precision medicine, phase I clinical trials with a special attention at the methodology to conduct these trials, as well as Head and Neck oncology. Christophe Le Tourneau is the principal investigator of numerous phase I and II trials, as well as of clinical trials in Head and Neck oncology.
He ran the first randomized precision medicine trial (SHIVA01) that compared the efficacy of matched targeted therapy versus conventional chemotherapy in patients with advances cancer. He has published 120+ peer-reviewed papers in international journals.
Title: Should every cancer patient be sequenced?
- Tumor sequencing has open the door of precision medicine in oncology
- Histology-agnostic treatment of cancer is now a reality with two anti cancer drugs approved across histologies based on specific molecular alterations
- While tumor sequencing should be performed in all patients with recurrent cancer, this should not be used to give off-label drugs